We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biologics Patent Debate Hinges on Equivalency Issue, Expert Says
Biologics Patent Debate Hinges on Equivalency Issue, Expert Says
August 24, 2005
Case law provides only inexact guidelines on just how much a protein sequence must vary in order to get around the patent on a biological therapy, according to a life sciences patent attorney.